Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
XBRANE.STthis companyXbrane Biopharma AB (publ)	SEK 12.25	122.01×	27.69×	101.88×	-939.14×	-167.5%	52.2%	-47.4%	83.5%	22.7%	-11.7%	-2.5%	0.1×	1.71×	-4.4×	7.12×	0.0%	2	-0.66	2	C+
ACTI.STActive Biotech AB	SEK 3.45	-166.06×	111.47×	0×	-170.4×	-98.9%	0.0%	0.0%	0.0%	-67.1%	-65.6%	-0.5%	0.03×	1.76×	0×	4.66×	0.0%	3	4.44	2	C+
ACUC.STAcuCort AB	SEK 0.40	-2.73×	1.12×	103.97×	-1.68×	-33.7%	-2670.0%	-3856.3%	-3812.2%	-41.1%	-41.6%	-34.8%	0×	1.02×	-90.73×	8.08×	0.0%	3	9.81	1	C-
ALZ.STAlzinova AB (publ)	SEK 0.33	-3.19×	0.68×	0×	-3.24×	-103.5%	0.0%	0.0%	0.0%	-21.5%	-20.9%	-47.5%	0.01×	-0.02×	-27.71×	0.11×	0.0%	3	5.43	2	C+
BIOSGN.STBiosergen AB	SEK 0.49	-20.76×	72.03×	0×	-20.37×	34.2%	0.0%	0.0%	0.0%	-347.0%	-351.9%	-4.3%	0×	0.38×	-4,139.3×	2.46×	0.0%	2	-8.67	—	—
BIOVIC-B.STBiovica International AB (publ)	SEK 0.32	-1.17×	0.95×	6.14×	-0.26×	-1052.3%	-523.5%	-523.5%	-522.1%	-80.9%	-76.5%	-77.0%	0.05×	1.07×	-176.89×	4.3×	0.0%	3	-9.24	2	C
Peer median	—	-3.19×	1.12×	0×	-3.24×	-98.9%	0.0%	0.0%	0.0%	-67.1%	-65.6%	-34.8%	0.01×	1.02×	-90.73×	4.3×	0.0%	3	4.44	2	—